Monday - September 16, 2024
UT-Southwestern Medical Center: Semaglutide Lowers Cardiovascular Risk Regardless of Blood Sugar
June 25, 2024
DALLAS, Texas, June 25 (TNSres) -- The University of Texas Southwestern Medical Center issued the following news release:

A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to a clinical trial including researchers from UT Southwestern Medical Center. The findings, published in Diabetes Care, also . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products